The Research Viral Vector Core (RVC) provides premium GLP recombinant Adeno-Associated Viral Vectors and Lentiviral Vectors for use in basic research and preclinical studies. A part of the Center for Cellular and Molecular Therapeutics at the Children's Hospital of Philadelphia, the RVC is dedicated to manufacturing top of the line vectors utilizing a fine tuned downstream process recognized internationally in industrial applications and academia. Capable of providing custom vector constructs at a variety of scales, The Research Vector Core offers state of the art technology and support for investigators interested in conducting viral based gene transfer.
Upon request, proviral plasmids can be amplified. Additionally, targets can be cloned into a proviral backbone.
Additional vector quality control services are available upon request. The core offers purity assessments, genomic, particle, and infectious titering, as well as mycoplasma, endotoxin, and bioburden assays.
With access to a wide range of host organisms, long-term expression in vivo, and low immunogenicity, recombinant Adeno-Associated viral vectors (rAAV) offer a robust and proven method of gene delivery. rAAV is a single stranded DNA parvovirus that infects both dividing and non-dividing cells with varying tissue tropisms and transduction efficiencies. It is highly popular in both the pre-clinical and clinical settings, capable of producing high titers for transgenes at maximum cassette limits of 4.7kb for single stranded vectors, and 2.2kb for self-complementary vectors. Our facility is equipped to manufacture rAAV at large scales with a production capacity of 2.0 x 1012 - 3.0 x 1015 viral genomes per week and can purify and concentrate vectors up to 1-5 x 1013vg/ml. Optimized for enhanced transduction efficiency and purified via CsCl gradient centrifugation, our final product contains over 99% packed capsid to ensure the highest effective potency in your application.
Recombinant Lentiviral vectors (rLV) constitute a powerful gene delivery system capable of reliably transducing both dividing and non-dividing cells. rLV integration into the host genome produces long-term, stable expression of a gene of interest of up to 9.5kb and can be pseudotyped with a wide variety of viral envelope glycoproteins to broaden desired tropism. The RVC produces 3rd generation Self-Inactivating (SIN) Lentiviral vectors minimizing the risk of replication-competent virus and offers both crude supernatant and highly purified vector concentrate for your specific research and pre-clinical requirements.